LXM 4
Alternative Names: LXM-4; LXM.4Latest Information Update: 03 Feb 2025
Price :
$50 *
At a glance
- Originator Laxxon Medical
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rheumatoid arthritis
Most Recent Events
- 23 Oct 2024 Laxxon Medical has patent pending for drug supply system in Mexico
- 23 Oct 2024 Laxxon Medical has patent protection for its drug delivery system in Australia
- 23 Oct 2024 Laxxon Medical has patent protection for methods of producing a drug delivery system in USA, China Australia and Japan